AbCellera Biologics Inc.
2125 East Mall, Suite 305
Vancouver
British Columbia
V6T 1Z4
Tel: 604-827-2128
Website: http://www.abcellera.com/
Email: info@abcellera.com
48 articles about AbCellera Biologics Inc.
-
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
9/15/2021
AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera’s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna
-
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
9/13/2021
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics).
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
AbCellera Announces Pricing of Initial Public Offering - Dec 11, 2020
12/11/2020
AbCellera Biologics Inc., a technology company that aims to become the centralized operating system for next-generation antibody discovery, announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
The two companies were able to get their antibody candidate into the clinic within two months of announcing their collaboration in response to the global pandemic.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
-
BioSpace Global Roundup, May 28
5/28/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
As part of the scale-up, it plans to hire up to 100 new staffers, bringing total headcount to about 240.
-
Minister Bains announces investment in antibody discovery technology to help treat COVID-19
5/3/2020
Government of Canada supports innovative project to combat COVID-19 and build Canadian capabilities to fight future pandemics
-
With the trillions of antibodies the human body can make, finding the antibody with the right combination of potency against a target and ease of manufacturing is, at best, an arduous, time-intensive endeavor for drug developers. AbCellera Biologics has developed a way to dramatically speed that ...
-
Under the terms of the agreement, AbCellera and Lilly have committed to equally share initial development costs towards a product, after which Lilly will be responsible for all further development, manufacturing and distribution.
-
AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19
3/12/2020
AbCellera and Lilly will select from 500+ unique antibodies isolated from one of the first U.S. patients who recovered from COVID-19 to create antibody therapeutics for treatment and prevention of COVID-19 [12-March-2020] VANCOUVER, British Columbia and INDIANAPOLIS , March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they
-
AbCellera Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020
3/10/2020
AbCellera, the antibody company, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2020 for its drug discovery platform that can search and analyze natural immune systems to deliver best-in-class antibody drugs.
-
INSERTING and REPLACING AbCellera Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020
3/10/2020
AbCellera, the antibody company, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2020 for its drug discovery platform that can search and analyze natural immune systems to deliver best-in-class antibody drugs.
-
Invetx Announces $15 Million Series A Financing and Industry-leading Partnerships for Animal Biopharmaceutical Development
2/24/2020
Invetx, a pioneering animal health biopharmaceutical company, announced a $15 million Series A financing and founding collaborations with WuXi Biologics and AbCellera.
-
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
-
China Coronavirus Update: Continued Spread, Run on Antivirals and Facemasks, Baby Diagnosed
2/6/2020
The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagn... -
AbCellera Is Mobilizing a Response to the Novel Coronavirus Outbreak as Part of Its DARPA P3 Program
1/28/2020
AbCellera confirms that it is mobilizing its pandemic response platform against the ongoing outbreak of a novel coronavirus (2019-nCoV) originating in Wuhan, China
-
AbCellera Announces the Issuance of Foundational Patent Claims Around Microfluidic Screening Assays for Antibody Discovery
11/7/2019
The patent, exclusively licensed to AbCellera, originated from Carl Hansen’s former laboratory at the University of British Columbia and lists Carl Hansen, Anupam Singhal, John Schrader, Charles Haynes, and Daniel Da Costa as co-inventors.